Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hope you had a reflective Indigenous Peoples Day. Today, we talk about the implications of Bristol Myers Squibb acquiring Mirati Therapeutics, see a new lung cancer test from liquid biopsy player Delfi Diagnostics, and more.
The need-to-know this morning
• Akero Therapeutics said its experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease. Adam Feuerstein has more details on the study outcome, and why Akero exeutives remains confident in the efficacy of its drug for patients with NASH cirrhosis. Investors are less sanguine: Akero shares are plunging in pre-market trading.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.